Insight

Jul 19, 2024, 13:45

Homologous recombination deficient breast cancer are more sensitive to chemo-radiotherapy

Memorial Sloan Kettering Radiation Oncology shared on X about a recent paper titled “Increased synthetic cytotoxicity of combinatorial chemo-radiotherapy in homologous recombination deficient tumors” in International Journal of Radiation Oncology, Biology, Physics.

Authors. Jennifer Ma, Rachna Shah, Andrew C. Bell, Jorge S. Reis-Filho, Nadeem Riaz, Simon N. Powell et al.

Homologous recombination

“New in International Journal of Radiation Oncology, Biology and Physics – The Red Journal from Dr Jennifer Ma et al: Homologous recombination deficient breast cancer (HRD via BRCA 1/2, functional test or mutational signature) are more sensitive to chemoRT vs isogenic controls or tumors without HRD mutational signature.”

Source: Memorial Sloan Kettering Radiation Oncology/X

Andrew C. Bell BRCA Breast Cancer cancer chemoRT IJROBP IJROBP - The Red Journal International Journal of Radiation Oncology Biology Physics Jennifer Ma Jorge S. Reis-Filho Memorial Sloan Kettering Radiation Oncology Nadeem Riaz OncoDaily Oncology Rachna Shah Simon N. Powell

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage